JO3479B1 - تركيبة دوائية مغلفة تحتوي على ريجورافنيب - Google Patents

تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Info

Publication number
JO3479B1
JO3479B1 JOP/2013/0268A JOP20130268A JO3479B1 JO 3479 B1 JO3479 B1 JO 3479B1 JO P20130268 A JOP20130268 A JO P20130268A JO 3479 B1 JO3479 B1 JO 3479B1
Authority
JO
Jordan
Prior art keywords
pharmaceutical composition
composition containing
coated pharmaceutical
containing regorafenib
regorafenib
Prior art date
Application number
JOP/2013/0268A
Other languages
English (en)
Inventor
Susanne Skrabs Dr
Ulrich Oberdieck Dr
Mayk Kresse Dr
Adrian Funke Dr
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3479(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of JO3479B1 publication Critical patent/JO3479B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة دوائية مغلفة تحتوي على regorafenib، hydrate، مادة منحلة (solvate)، مادة أيض (metabolite) أو ملح (salt) مقبول دوائيا من ذلك أو متعدد أشكال (polymorph) من ذلك وبعملية تحضيرها وباستخدامها لمعالجة اضطرابات.
JOP/2013/0268A 2012-09-06 2013-09-04 تركيبة دوائية مغلفة تحتوي على ريجورافنيب JO3479B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12183331 2012-09-06

Publications (1)

Publication Number Publication Date
JO3479B1 true JO3479B1 (ar) 2020-07-05

Family

ID=46963450

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0268A JO3479B1 (ar) 2012-09-06 2013-09-04 تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Country Status (43)

Country Link
US (1) US20140065212A1 (ar)
EP (2) EP2892507B1 (ar)
JP (1) JP6445436B2 (ar)
KR (1) KR102162036B1 (ar)
CN (5) CN116392598A (ar)
AP (1) AP2015008292A0 (ar)
AR (1) AR092439A1 (ar)
AU (1) AU2013312531B2 (ar)
BR (1) BR112015004936B1 (ar)
CA (1) CA2883767C (ar)
CL (1) CL2015000544A1 (ar)
CO (1) CO7310528A2 (ar)
CR (1) CR20150114A (ar)
CU (1) CU24244B1 (ar)
CY (1) CY1118839T1 (ar)
DK (1) DK2892507T3 (ar)
EA (1) EA027685B1 (ar)
ES (1) ES2623205T3 (ar)
GT (1) GT201500053A (ar)
HK (1) HK1214170A1 (ar)
HR (1) HRP20170620T1 (ar)
HU (1) HUE032758T2 (ar)
IL (1) IL237350B (ar)
IN (1) IN2015DN01673A (ar)
JO (1) JO3479B1 (ar)
LT (1) LT2892507T (ar)
MA (1) MA37888B1 (ar)
MX (1) MX359922B (ar)
MY (1) MY176135A (ar)
NZ (1) NZ705578A (ar)
PE (1) PE20151005A1 (ar)
PH (1) PH12015500460B1 (ar)
PL (1) PL2892507T3 (ar)
PT (1) PT2892507T (ar)
RS (1) RS56019B1 (ar)
SA (1) SA515360113B1 (ar)
SG (1) SG11201501683WA (ar)
SI (1) SI2892507T1 (ar)
TW (1) TWI640329B (ar)
UA (1) UA115994C2 (ar)
UY (1) UY35006A (ar)
WO (1) WO2014039677A1 (ar)
ZA (1) ZA201501394B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2016531151A (ja) * 2013-09-13 2016-10-06 バイエル ファーマ アクチエンゲゼルシャフト レファメチニブを含有する医薬組成物
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN105496975B (zh) * 2015-12-17 2019-01-04 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
CA3244313A1 (en) * 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
BR112021000156A2 (pt) * 2018-07-06 2021-04-06 Agios Pharmaceuticals, Inc. Formas de ivosidenib e composições farmacêuticas
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN113018274A (zh) * 2021-03-10 2021-06-25 药源生物科技（启东）有限公司 一种含羟丙甲纤维素的药物组合物及其制备方法
TR2023002707A2 (tr) * 2023-03-10 2024-09-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Regorafenib içeren bir farmasötik bileşim.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272504A1 (en) * 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
CN1265793C (zh) * 2002-11-18 2006-07-26 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP2009519266A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア類
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
JP5351490B2 (ja) * 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물

Also Published As

Publication number Publication date
IL237350B (en) 2020-11-30
CN111249247A (zh) 2020-06-09
CN116392484A (zh) 2023-07-07
DK2892507T3 (en) 2017-05-01
TW201414510A (zh) 2014-04-16
HRP20170620T1 (hr) 2017-06-30
HK1214170A1 (zh) 2016-07-22
PH12015500460A1 (en) 2015-04-20
CN116392485A (zh) 2023-07-07
CO7310528A2 (es) 2015-06-30
IN2015DN01673A (ar) 2015-07-03
RS56019B1 (sr) 2017-09-29
EA201590520A1 (ru) 2015-10-30
KR102162036B1 (ko) 2020-10-07
EP2892507A1 (en) 2015-07-15
ES2623205T3 (es) 2017-07-10
BR112015004936B1 (pt) 2022-12-06
PH12015500460B1 (en) 2015-04-20
CL2015000544A1 (es) 2015-08-21
PE20151005A1 (es) 2015-06-27
PL2892507T3 (pl) 2017-09-29
MA37888B1 (fr) 2019-08-30
TWI640329B (zh) 2018-11-11
EP2892507B1 (en) 2017-02-01
MX359922B (es) 2018-10-16
SG11201501683WA (en) 2015-04-29
MY176135A (en) 2020-07-24
ZA201501394B (en) 2016-07-27
CU24244B1 (es) 2017-02-02
US20140065212A1 (en) 2014-03-06
UA115994C2 (uk) 2018-01-25
CA2883767C (en) 2018-11-13
CN116392598A (zh) 2023-07-07
LT2892507T (lt) 2017-06-12
CA2883767A1 (en) 2014-03-13
CN104902878A (zh) 2015-09-09
AR092439A1 (es) 2015-04-22
AU2013312531B2 (en) 2017-10-19
GT201500053A (es) 2015-10-12
MX2015002815A (es) 2015-05-15
UY35006A (es) 2014-03-31
EA027685B1 (ru) 2017-08-31
HUE032758T2 (en) 2017-10-30
JP6445436B2 (ja) 2018-12-26
CU20150020A7 (es) 2015-05-28
CR20150114A (es) 2015-05-11
IL237350A0 (en) 2015-04-30
NZ705578A (en) 2017-10-27
BR112015004936A2 (pt) 2017-07-04
EP3243508A1 (en) 2017-11-15
AP2015008292A0 (en) 2015-02-28
CY1118839T1 (el) 2018-01-10
KR20150048872A (ko) 2015-05-07
AU2013312531A1 (en) 2015-03-12
PT2892507T (pt) 2017-05-02
SA515360113B1 (ar) 2016-08-10
WO2014039677A1 (en) 2014-03-13
MA37888A1 (fr) 2018-07-31
JP2015527395A (ja) 2015-09-17
SI2892507T1 (sl) 2017-08-31

Similar Documents

Publication Publication Date Title
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
IN2014DN07897A (ar)
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
IN2014DN10683A (ar)
IN2013MU03838A (ar)